AI Article Synopsis
- The RENOTORCH study compared the effectiveness and safety of toripalimab (an immune checkpoint inhibitor) combined with axitinib (a tyrosine kinase inhibitor) versus sunitinib for treating advanced clear cell renal cell carcinoma (RCC).
- Out of 421 patients, those receiving toripalimab plus axitinib had a 35% lower risk of disease progression and longer median progression-free survival (18 months) compared to those on sunitinib (9.8 months).
- The study also found a significantly higher overall response rate in the toripalimab-axitinib group (56.7%) versus sunitinib (30.8%), although treatment-related serious adverse events were
Article Abstract
Background: Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III RENOTORCH study compared the efficacy and safety of toripalimab plus axitinib versus sunitinib for the first-line treatment of patients with intermediate-/poor-risk advanced RCC.
Patients And Methods: Patients with intermediate-/poor-risk unresectable or metastatic RCC were randomized in a ratio of 1 : 1 to receive toripalimab (240 mg intravenously once every 3 weeks) plus axitinib (5 mg orally twice daily) or sunitinib [50 mg orally once daily for 4 weeks (6-week cycle) or 2 weeks (3-week cycle)]. The primary endpoint was progression-free survival (PFS) assessed by an independent review committee (IRC). The secondary endpoints were investigator-assessed PFS, overall response rate (ORR), overall survival (OS), and safety.
Results: A total of 421 patients were randomized to receive toripalimab plus axitinib (n = 210) or sunitinib (n = 211). With a median follow-up of 14.6 months, toripalimab plus axitinib significantly reduced the risk of disease progression or death by 35% compared with sunitinib as assessed by an IRC [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.49-0.86; P = 0.0028]. The median PFS was 18.0 months in the toripalimab-axitinib group, whereas it was 9.8 months in the sunitinib group. The IRC-assessed ORR was significantly higher in the toripalimab-axitinib group compared with the sunitinib group (56.7% versus 30.8%; P < 0.0001). An OS trend favoring toripalimab plus axitinib was also observed (HR 0.61, 95% CI 0.40-0.92). Treatment-related grade ≥3 adverse events occurred in 61.5% of patients in the toripalimab-axitinib group and 58.6% of patients in the sunitinib group.
Conclusion: In patients with previously untreated intermediate-/poor-risk advanced RCC, toripalimab plus axitinib provided significantly longer PFS and higher ORR than sunitinib and had a manageable safety profile TRIAL REGISTRATION: ClinicalTrials.gov NCT04394975.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annonc.2023.09.3108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study.
Signal Transduct Target Ther
October 2024
Department of Urology, Chinese PLA General Hospital, Beijing, China.
Article Synopsis
- The NEOTAX phase 2 study explored how effective and safe the combination of toripalimab and axitinib is for patients with clear cell renal cell carcinoma and inferior vena cava tumor thrombus.
- Out of 25 patients, 44% showed a reduction in thrombus level, with a median decrease in tumor thrombus length of 2.3 cm, while 61.9% had changes in their surgical approach.
- The study found promising progression-free survival rates (25.3 months median; 89.1% at 1 year) and noted no severe treatment-related adverse events, suggesting that the combination therapy effectively downstages the tumor and improves surgical outcomes.
Administering immunotherapy after anti-vascular targeted therapy improves overall survival of patients with metastatic clear cell renal cell carcinoma.
J Cancer
June 2024
Affiliated Cancer Hospital of Shandong First Medical University, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China.
Article Synopsis
- The FDA has approved various treatments for advanced metastatic renal cell carcinoma (mRCC), which includes both anti-vascular TKIs and immune checkpoint inhibitors (ICIs), but selecting the best treatment order for improved survival is still unclear.
- This study aimed to assess the overall survival (OS) and progression-free survival (PFS) in mRCC patients based on treatment sequences involving TKIs and anti PD-1 therapies at a cancer hospital in Shandong, China.
- Analysis involved 135 patients and highlighted that the treatment order affected survival outcomes, with some receiving anti PD-1 alone or combined with TKIs, allowing for comparisons of their effectiveness.
Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial.
J Immunother Cancer
June 2024
Department of Urology, RenJi Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
Article Synopsis
- - The study investigates the safety and effectiveness of combining toripalimab, an immune checkpoint inhibitor, with axitinib for treating non-metastatic clear cell renal cell carcinoma, focusing on clinical outcomes and biomarkers.
- - Conducted as a single-arm phase II trial with 20 enrolled patients, results showed a 45% objective response rate (ORR), with significant tumor shrinkage in 95% of participants before surgery.
- - Adverse events occurred in 25% of patients, including hypertension and elevated liver enzymes, while responders exhibited notable differences in certain immune factors compared to those with stable disease.
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis.
Expert Rev Pharmacoecon Outcomes Res
June 2024
Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, PR China.
Article Synopsis
- - The study assessed the cost-effectiveness of toripalimab combined with axitinib versus sunitinib for treating advanced renal cell carcinoma (RCC) in Chinese patients using a survival model over a 20-year period.
- - Results showed that toripalimab plus axitinib provided an additional 1.19 life-years and 0.65 quality-adjusted life-years but came with a higher cost of about $41,499, leading to an incremental cost-effectiveness ratio (ICER) of $64,337.49 per QALY, which exceeds the willingness-to-pay (WTP) threshold.
- - The conclusion indicated that this combination treatment is unlikely to be considered cost-effective as a first-line
Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma.
Ann Oncol
February 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing. Electronic address:
Article Synopsis
- The study investigated the effectiveness of toripalimab and axitinib as neoadjuvant therapy for patients with resectable mucosal melanoma, aiming to improve pathological response rates after treatment.* -
- Out of 29 patients treated, 24 underwent surgery, with a 33.3% pathologic response rate noted, which included complete and partial responses.* -
- Results showed tolerability of the therapy with some adverse events, while increased tumor-infiltrating lymphocytes were observed in responders, indicating a potential immune response enhancement.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!